Guangzhou Byte Song Pharmaceutical Technology

Guangzhou Byte Song Pharmaceutical Technology is an AI-driven biotechnology company focused on the discovery and development of innovative small molecule drugs for "undruggable" targets. Utilizing its proprietary ByteSong AI platform, the company integrates computational chemistry, structural biology, and machine learning to identify novel allosteric binding sites and protein-protein interaction (PPI) inhibitors. The company's primary therapeutic focus lies in oncology and immunology, aiming to address significant unmet medical needs through precision medicine. Byte Song Pharmaceutical is headquartered in Guangzhou, China, and has secured significant venture capital funding to advance its early-stage pipeline. The firm's approach combines high-performance computing with experimental validation to accelerate the development of high-potency, high-selectivity drug candidates.